abobotulinumtoxinA
Trade name: Dysport
Biologicalapproved
Approved
Apr 29, 2009
Botulinum toxin, or botulinum neurotoxin, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent. — Wikipedia
Clinical trial activity
79 trials · 82 clinical orgs · 1 marketing orgs
Phase 1
13
Phase 2
38
Phase 3
26
Phase 4
16
Earliest trial started May 1, 2007 (NCT00460564)
Timeline
Indications
Approved for
Studied for
- Arteries · Phase 2
- Beckwith-Wiedemann Syndrome · Phase 3
- Blepharitis · Phase 3
- Blepharospasm · Phase 4
- Botulinum Toxins · Phase 2
- Botulinum Toxins, Type A · Phase 4
- Brain Injuries, Traumatic · Phase 2
- Bruxism · Phase 3
- Cerebral Palsy · Phase 3
- Chronic Exertional Compartment Syndrome · Phase 2
- Complex Regional Pain Syndromes · Early Phase 1
- Cystitis, Interstitial · Early Phase 1
- Dermatology · Phase 2/Phase 3
- Dyspareunia · Phase 4
- Electromyography · Phase 3
- Epidermolysis Bullosa Simplex · Phase 2/Phase 3
- Erectile Dysfunction · Phase 2
- Facial Pain · Phase 2
- Fasciitis, Plantar · Phase 2
- Fecal Incontinence · Phase 3
- Hemifacial Spasm · Phase 4
- Hernia, Abdominal · Phase 2
- Hernia, Ventral · Phase 2
- Hyperhidrosis · Phase 3
- Jaw · Phase 2
- Leg Injuries · Phase 4
- Lip Diseases · Early Phase 1
- Muscle Spasticity · Phase 4
- Musculoskeletal Diseases · Phase 3
- Neoplasms · Phase 3
- Pain · Phase 3
- Pelvic Floor Disorders · Phase 3
- Pelvic Pain · Phase 4
- Pelvis · Phase 4
- Popliteal Artery Entrapment Syndrome · Phase 2
- Post-Traumatic Headache · Phase 4
- Prostatic Hyperplasia · Phase 4
- Raynaud Disease · Phase 4
- Rhytidoplasty · Phase 4
- Sclerosis · Phase 3
- Scoliosis · Phase 4
- Shoulder Pain · Phase 4
- Spastic Paraplegia, Hereditary · Phase 2/Phase 3
- Strabismus · Phase 3
- Stroke · Phase 4
- Talipes · Phase 4
- Urinary Bladder, Overactive · Phase 4
- Urinary Incontinence · Phase 1/Phase 2
- Urinary Incontinence, Stress · Phase 3
- Urinary Incontinence, Urge · Phase 3
- Urination Disorders · Early Phase 1
Mechanism of action
Approval history
- approvedApr 29, 2009
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBotulinum toxin ↗
Also known as
- dwp450-004
- dysport
- dysport
- dysport
- gsk1358820
- hugeltox
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07082972 | Phase 4 | Sep 1, 2025 | Istanbul University |
| NCT07013240 | Phase 3 | Jul 5, 2025 | University of Bordeaux |
| NCT06946160 | Phase 3 | May 28, 2024 | Espad Pharmed |
| NCT06271395 | N/A | Feb 28, 2024 | Allina Health, Zhengzhou University |
| NCT07266064 | N/A | Jan 2, 2024 | Gazi University, Yuksek Ihtisas University |
| NCT05874154 | N/A | Jan 1, 2024 | University of Lyon |
| NCT06174155 | N/A | Dec 15, 2023 | Cairo University |
| NCT05998187 | Phase 3 | Dec 1, 2023 | Rouen Normandy University |
| NCT05910983 | N/A | Dec 1, 2023 | Menoufia University |
| NCT05606757 | Phase 2 | May 22, 2023 | AbbVie |
| NCT05804656 | Phase 3 | Apr 13, 2023 | CKD Bio Corporation |
| NCT05393921 | Phase 4 | Feb 1, 2023 | Case Western Reserve University |
| NCT05512039 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2023 | Dartmouth University, Kaiser Permanente, Oregon Health and Science University, Patient-Centered Outcomes Research Institute, Stanford University, University of Alabama, Birmingham, University of Connecticut, University of Pittsburgh, University of Texas, Galveston |
| NCT05673655 | Phase 2 | Dec 25, 2022 | Fayoum University |
| NCT05466539 | Phase 4 | Nov 30, 2022 | Emory University, Ipsen |
| NCT05627921 | N/A | Nov 15, 2022 | Marmara University |
| NCT05623410 | Phase 3 | Oct 11, 2022 | ATGC Co., Ltd. |
| NCT05565950 | Phase 1/Phase 2 (Phase 2) | Oct 3, 2022 | Eirion Therapeutics |
| NCT05652036 | Phase 4 | Jul 7, 2022 | The University of Texas, Dallas |
| NCT05428930 | Phase 1 | Jun 22, 2022 | Chung-Ang University, CKD Bio Corporation |
Showing 20 of 79 trials
Page 1 / 4
Organizations
Research & Development (82)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 8 | 8 | 1 | 2007 |
| CKD Bio Corporation | For profit | 4 | 4 | 2 | 2022 |
| Ipsen | For profit | 4 | 2 | 2 | 2013 |
| Q-Med AB | For profit | 4 | 4 | 3 | 2018 |
| Stanford University | Academic/Hospital | 4 | 3 | 2 | 2018 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 3 | 3 | 3 | 2014 |
| Cairo University | Academic/Hospital | 3 | 2 | 3 | 2016 |
| Daewoong Pharmaceutical Co. LTD. | For profit | 3 | 3 | 2 | 2014 |
| Benha University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Chung-Ang University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Department of Veteran Affairs | Government | 2 | 2 | 2 | 2013 |
| EuBiologics Co.,Ltd | For profit | 2 | 2 | 2 | 2019 |
| Galderma | For profit | 2 | 0 | 2 | 2016 |
| Kaiser Permanente | Academic/Hospital | 2 | 0 | 2 | 2020 |
| The University of Texas, Dallas | Academic/Hospital | 2 | 1 | 2 | 2020 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 0 | 2 | 2020 |
| University of Lyon | Academic/Hospital | 2 | 2 | 2 | 2019 |
| University of Pennsylvania | Academic/Hospital | 2 | 1 | 2 | 2020 |
| University of Pittsburgh | Academic/Hospital | 2 | 0 | 2 | 2020 |
| AbbVie | For profit | 1 | 1 | 1 | 2023 |
82 organizations
Page 1 / 5